SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001628280-24-029561
Filing Date
2024-06-24
Accepted
2024-06-24 16:01:28
Documents
16
Period of Report
2024-03-27
Items
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K/A avtx-20240327.htm   iXBRL 8-K/A 31931
2 EX-23.1 ex-231eyconsentrestated.htm EX-23.1 2470
3 EX-99.1 ex-991almatarestatedaudite.htm EX-99.1 185080
4 EX-99.2 ex-992almatarestatedprofor.htm EX-99.2 134618
  Complete submission text file 0001628280-24-029561.txt   510596

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT avtx-20240327.xsd EX-101.SCH 1969
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT avtx-20240327_lab.xml EX-101.LAB 21026
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT avtx-20240327_pre.xml EX-101.PRE 12041
19 EXTRACTED XBRL INSTANCE DOCUMENT avtx-20240327_htm.xml XML 2627
Mailing Address 540 GAITHER ROAD SUITE 400 ROCKVILLE MD 20850
Business Address 540 GAITHER ROAD SUITE 400 ROCKVILLE MD 20850 410-522-8707
Avalo Therapeutics, Inc. (Filer) CIK: 0001534120 (see all company filings)

IRS No.: 450705648 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-37590 | Film No.: 241064201
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)